GlassScriptPhysician profile
Thomas C Chapman
NPI 1932167897
$4,226.03
in general payments reported to CMS, 2019-2025
46 companies · $787 in 2025
The $787 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $917 · 2020: $217 · 2021: $639 · 2022: $880 · 2023: $153 · 2024: $634 · 2025: $787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,573.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $868.59 | 2019-2025 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $301.21 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $297.31 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Novo Nordisk INC | $238.60 | 2019-2022 | |
| Glaxosmithkline, LLC. | $226.82 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $214.10 | 2019-2022 | |
| Abbott Laboratories | $206.40 | 2019-2025 | Freestyle Libre 3 |
| Amgen INC. | $179.06 | 2019-2025 | Repatha, Otezla |
| Allergan, INC. | $147.38 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $141.52 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.58 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $109.94 | 2020-2023 | Qelbree |
| Eisai INC. | $106.71 | 2025 | |
| Pfizer INC. | $95.43 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $87.28 | 2020-2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Chapman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.